| scholarly article | Q13442814 |
| P50 | author | Heng Fong Seow | Q39829549 |
| P2093 | author name string | Wai Kien Yip | |
| Theodora Fifis | |||
| P2860 | cites work | KRASMutation Signature in Colorectal Tumors Significantly Overlaps With the Cetuximab Response Signature | Q58408249 |
| Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial | Q58614513 | ||
| PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients | Q58813317 | ||
| Lung recurrence after curative surgery for colorectal cancer | Q69056189 | ||
| Expression of c-met proto-oncogene in primary colorectal cancer and liver metastases | Q74073409 | ||
| Protein bound polysaccharide PSK abrogates more efficiently experimental metastases derived from H-2 negative than from H-2 positive fibrosarcoma tumor clones | Q74319890 | ||
| Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer | Q77555522 | ||
| Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab | Q80704669 | ||
| Novel Wnt antagonists target porcupine and Axin | Q83195416 | ||
| Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma | Q83780031 | ||
| Effects of preoperative immunochemoradiotherapy and chemoradiotherapy on immune responses in patients with rectal adenocarcinoma | Q84066313 | ||
| A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014 | Q85329118 | ||
| Global cancer statistics | Q22241238 | ||
| Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer | Q24563539 | ||
| Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | Q24597152 | ||
| Markers of resistance to anti-EGFR therapy in colorectal cancer | Q24598640 | ||
| Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab | Q24600031 | ||
| Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response | Q24602822 | ||
| Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer | Q24604601 | ||
| TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice | Q24606406 | ||
| MicroRNAs: target recognition and regulatory functions | Q24609584 | ||
| Comprehensive molecular characterization of human colon and rectal cancer | Q24630415 | ||
| The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors | Q24631515 | ||
| The PI3K pathway as drug target in human cancer | Q24632283 | ||
| Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance | Q24645668 | ||
| Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect--a histopathological and immunohistochemical study | Q24801703 | ||
| Combining radiotherapy and cancer immunotherapy: a paradigm shift | Q27021428 | ||
| A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies | Q27675148 | ||
| Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. | Q27824811 | ||
| KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. | Q27824867 | ||
| KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. | Q27851422 | ||
| K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 | ||
| Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer | Q27851456 | ||
| PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies | Q27851465 | ||
| Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. | Q27851485 | ||
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Q27851573 | ||
| Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer | Q27851696 | ||
| Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer | Q27851708 | ||
| Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. | Q27851711 | ||
| A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. | Q27851748 | ||
| A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer | Q27851787 | ||
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. | Q27852431 | ||
| Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. | Q27853074 | ||
| First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors | Q27853088 | ||
| Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients | Q27853121 | ||
| Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans | Q27860867 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| TOR, a central controller of cell growth | Q27933354 | ||
| Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial | Q28036747 | ||
| Molecular pathways: novel approaches for improved therapeutic targeting of Hedgehog signaling in cancer stem cells | Q28081405 | ||
| Therapeutic genome editing: prospects and challenges | Q28087380 | ||
| High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 | ||
| Notch signaling: from the outside in | Q28139768 | ||
| Hedgehog signaling in animal development: paradigms and principles | Q28208463 | ||
| Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer | Q28240089 | ||
| Sonic Hedgehog-dependent proliferation in a series of patients with colorectal cancer | Q28240244 | ||
| Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated | Q28245528 | ||
| Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer | Q28271324 | ||
| Tissue repair and stem cell renewal in carcinogenesis | Q28294006 | ||
| Identification of an amplified, highly expressed gene in a human glioma | Q28300727 | ||
| The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers | Q29395525 | ||
| mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt | Q29547767 | ||
| Distinct role of macrophages in different tumor microenvironments | Q29614304 | ||
| Macrophages, innate immunity and cancer: balance, tolerance, and diversity | Q29614352 | ||
| Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis | Q29614405 | ||
| Developmental roles and clinical significance of hedgehog signaling | Q29614988 | ||
| Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer | Q29616163 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| Targeting PI3K signalling in cancer: opportunities, challenges and limitations | Q29617685 | ||
| Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer | Q29618030 | ||
| Insulin and insulin-like growth factor signalling in neoplasia | Q29619495 | ||
| Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study | Q29619653 | ||
| Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates | Q29620051 | ||
| Macrophage regulation of tumor responses to anticancer therapies | Q34649588 | ||
| PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic color | Q34660907 | ||
| FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial | Q34663697 | ||
| Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells | Q34733788 | ||
| More complicated than it looks: assembly of Notch pathway transcription complexes | Q34817647 | ||
| Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation | Q35000446 | ||
| Expanded RAS: refining the patient population | Q35102475 | ||
| Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer | Q35161368 | ||
| c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases | Q35199181 | ||
| Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer | Q35351133 | ||
| Can we safely target the WNT pathway? | Q35591995 | ||
| Vascular targeting agents | Q35642613 | ||
| A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours | Q35677661 | ||
| Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis | Q35747184 | ||
| 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors | Q35778060 | ||
| The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models | Q35835097 | ||
| EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib | Q35841043 | ||
| A phase II study of RO4929097 in metastatic colorectal cancer | Q35910545 | ||
| Drug rechallenge and treatment beyond progression--implications for drug resistance. | Q35967416 | ||
| Primary tumor location as a prognostic factor in metastatic colorectal cancer. | Q36047405 | ||
| Loss of WNT-TCF addiction and enhancement of HH-GLI1 signalling define the metastatic transition of human colon carcinomas | Q36088885 | ||
| Oncogenic Ras in tumour progression and metastasis | Q36103287 | ||
| Combining radiation and immunotherapy for synergistic antitumor therapy. | Q36326598 | ||
| Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody | Q36544926 | ||
| The epidermal growth factor receptor pathway: a model for targeted therapy | Q36603677 | ||
| Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy | Q36610301 | ||
| PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients | Q36611365 | ||
| The many ways of Wnt in cancer | Q36701583 | ||
| TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. | Q36731174 | ||
| The biology of cancer stem cells | Q36888991 | ||
| Recurrent R-spondin fusions in colon cancer | Q36949683 | ||
| A colorectal cancer classification system that associates cellular phenotype and responses to therapy | Q37175913 | ||
| Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion | Q37242449 | ||
| Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. | Q37349748 | ||
| Survival of patients with hereditary colorectal cancer: comparison of HNPCC and colorectal cancer in FAP patients with sporadic colorectal cancer. | Q50535412 | ||
| Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO | Q50976831 | ||
| Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer. | Q51542320 | ||
| Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. | Q52049364 | ||
| Clinical development of vascular disrupting agents: what lessons can we learn from ASA404? | Q52613053 | ||
| DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular. | Q52619102 | ||
| Increasing complexity of Ras signaling. | Q53429989 | ||
| Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. | Q54401988 | ||
| EGFR FISH in colorectal cancer: what is the current reality? | Q54534460 | ||
| Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. | Q55043614 | ||
| Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. | Q55476488 | ||
| Colorectal Tumors Are Effectively Eradicated by Combined Inhibition of -Catenin, KRAS, and the Oncogenic Transcription Factor ITF2 | Q57748874 | ||
| Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II) | Q58023765 | ||
| Prostaglandin E2 Stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer | Q40420990 | ||
| Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer | Q40519878 | ||
| CXCR4 and CXCL12 Expression in Rectal Tumors of Stage IV Patients Before and After Local Radiotherapy and Systemic Neoadjuvant Treatment | Q41627200 | ||
| Hedgehog signalling in colon cancer and stem cells | Q41976019 | ||
| Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. | Q42282551 | ||
| Deregulation of the hedgehog signalling pathway: a possible role for the PTCH and SUFU genes in human rhabdomyoma and rhabdomyosarcoma development | Q42486654 | ||
| Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma | Q42496244 | ||
| Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity | Q42775676 | ||
| A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. | Q44030346 | ||
| Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate. | Q44293477 | ||
| International trends in colorectal cancer incidence rates | Q44546922 | ||
| Stability and association of Smoothened, Costal2 and Fused with Cubitus interruptus are regulated by Hedgehog | Q44605502 | ||
| Effect of PSK on the maturation of dendritic cells derived from human peripheral blood monocytes | Q44798732 | ||
| Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment | Q44820379 | ||
| GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab | Q44823741 | ||
| Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study | Q45276051 | ||
| Target identification for a Hedgehog pathway inhibitor reveals the receptor GPR39. | Q46244118 | ||
| Identification of Modulators of TRAIL-Induced Apoptosis via RNAi-Based Phenotypic Screening | Q47585614 | ||
| Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial | Q29620127 | ||
| Activating mutations in TOR are in similar structures as oncogenic mutations in PI3KCalpha | Q30437618 | ||
| Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data | Q30862367 | ||
| Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex | Q31038919 | ||
| A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected] | Q31106002 | ||
| Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results | Q33149039 | ||
| Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow | Q33150747 | ||
| Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study | Q33359798 | ||
| Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer | Q33389767 | ||
| Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer | Q33397708 | ||
| Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial | Q33405554 | ||
| ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancer | Q33662919 | ||
| Targeting CD137 enhances the efficacy of cetuximab. | Q33872482 | ||
| Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer | Q33913953 | ||
| Tumor-associated macrophages as an emerging target against tumors: Creating a new path from bench to bedside | Q34042993 | ||
| Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer | Q34094717 | ||
| Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. | Q34099883 | ||
| Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer | Q34249997 | ||
| Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials | Q34263478 | ||
| A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. | Q34282412 | ||
| Hedgehog signalling in cancer formation and maintenance | Q34291589 | ||
| Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors | Q34323825 | ||
| First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement | Q34324970 | ||
| Self-renewal as a therapeutic target in human colorectal cancer. | Q34388958 | ||
| Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study | Q34411696 | ||
| In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities | Q34466574 | ||
| Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group | Q34511070 | ||
| Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines | Q34526671 | ||
| Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. | Q34554584 | ||
| Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. | Q34590731 | ||
| Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen | Q34642136 | ||
| Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial | Q34645599 | ||
| Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody | Q37351567 | ||
| A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). | Q37407616 | ||
| The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies | Q37548858 | ||
| DriverDB: an exome sequencing database for cancer driver gene identification. | Q37661903 | ||
| Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer | Q37760111 | ||
| Targeting Wnt signaling: can we safely eradicate cancer stem cells? | Q37763415 | ||
| The utility of hedgehog signaling pathway inhibition for cancer | Q38031211 | ||
| Cell-autonomous and non-cell-autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: from basic research to a clinical perspective | Q38125434 | ||
| Genome-wide association and sequencing studies on colorectal cancer. | Q38149684 | ||
| MEK in cancer and cancer therapy | Q38152195 | ||
| Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma | Q38207042 | ||
| Recent advances in the design of Hedgehog pathway inhibitors for the treatment of malignancies | Q38213666 | ||
| Targeting PI3 kinase in cancer | Q38252866 | ||
| Targeting the TGFβ pathway for cancer therapy. | Q38274752 | ||
| Functional expression of HGF and its receptor in human colorectal cancer | Q38310805 | ||
| Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies | Q38363276 | ||
| Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab | Q38420145 | ||
| Rectal and colon cancer: Not just a different anatomic site. | Q38543019 | ||
| PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab | Q38584695 | ||
| An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. | Q38712061 | ||
| Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer | Q38919853 | ||
| TGFα and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells | Q38986009 | ||
| Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents | Q39224151 | ||
| Hedgehog Gli3 activator signal augments tumorigenicity of colorectal cancer via upregulation of adherence-related genes | Q39240013 | ||
| Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation | Q39241023 | ||
| Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer | Q39488860 | ||
| Hedgehog signaling drives cellular survival in human colon carcinoma cells | Q39623310 | ||
| Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance | Q39625099 | ||
| Symmetric division versus asymmetric division: a tale of two coactivators | Q39696686 | ||
| Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease | Q39720433 | ||
| PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers | Q39859169 | ||
| gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity | Q39894711 | ||
| Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. | Q40350197 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| colorectal carcinoma | Q25493920 | ||
| P304 | page(s) | 1899-1920 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | OncoTargets and Therapy | Q7092081 |
| P1476 | title | Advances in targeted and immunobased therapies for colorectal cancer in the genomic era | |
| P478 | volume | 9 |
| Q39416850 | A unified pathogenesis for kidney diseases, including genetic diseases and cancers, by the protein-homeostasis-system hypothesis |
| Q37381487 | Co-delivery of doxorubicin and recombinant plasmid pHSP70-Plk1-shRNA by bacterial magnetosomes for osteosarcoma therapy |
| Q92617884 | Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer |
| Q33884437 | Hedgehog signaling pathway in colorectal cancer: function, mechanism, and therapy |
| Q46465597 | Infrequently expressed miRNAs influence survival after diagnosis with colorectal cancer |
| Q47118009 | Liposomal 64Cu-PET Imaging of Anti-VEGF Drug Effects on Liposomal Delivery to Colon Cancer Xenografts |
| Q26740310 | Manipulation of DNA Repair Proficiency in Mouse Models of Colorectal Cancer |
| Q37593796 | Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study |
| Q92266428 | Serum PlGF and EGF are independent prognostic markers in non-metastatic colorectal cancer |
| Q52320729 | Strategy to targeting the immune resistance and novel therapy in colorectal cancer. |
| Q48234912 | Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. |
| Q28066460 | The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care |
| Q38638847 | The colorectal cancer immune microenvironment and approach to immunotherapies. |
| Q52723896 | The reversal effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism. |
| Q47126863 | Therapeutic effects of the euglenoid ichthyotoxin, euglenophycin, in colon cancer. |
| Q58122181 | and Colorectal Cancer |
Search more.